(14th July, 2014); NIPER, Hyderbad is all set to develop National Centre for Research & Development in Bulk Drug (NCRDBD) for filling up gap in Research and Development in bulk drugs. The over all project costs around more than 52 crore rupees and with an operating cost of over 37 crore rupees for five years.
There are nearly 2500 bulk drugs manufacturing units in India. The estimated turnover of the Bulk Drug Industry in 2012-13 was around 12.5 billion US dollars.
The industry has shown a Cumulative Annual Growth Rate (CAGR) of 17 percent in the last three years and has a share of about 10% of the global bulk drugs market of about US$ 110 Billion. However, the import of Bulk Drugs has seen a CAGR of 18% during last three years indicating an increasing level of dependence on international supply for this critical input of pharmaceutical sector. This is further compounded by the fact that more than 60% share in imports of Intermediate for Active pharmaceutical ingredients is from a single country.
The performance of Bulk Drug sector is one of the critical factors that affect the overall efficiency and cost competitiveness of the pharmaceutical sector. The centre is to be set up to urgently address these concerns and make the industry cost competitive. In Bulk Drug Industry, the reduced processes and improved technology can help in reducing the cost significantly.
NCRDBD will provide centralized research facilities and technologies, analytical facilities and consulting services for process improvement and optimization. It would give special emphasis to the empowerment of MSME sector. The Pharmacy Industry specially the SME sector requires such center since the individual units cannot afford to have their captive R&D facilities.
In short, it would be an innovative R&D provider in the field of bulk drugs and offer competitive and eco-friendly technologies in specified areas products and processes.
